GYRE

Gyre Therapeutics (GYRE)

About Gyre Therapeutics (GYRE)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Details

Daily high

$6.34

Daily low

$6.09

Price at open

$6.20

52 Week High

$9.42

52 Week Low

$5.44

Market cap

606.2M

Dividend yield

0.00%

Volume

75,757

Avg. volume

93,115

P/E ratio

-80.33

Gyre Therapeutics News